Acropolis Investment Management LLC Has $397,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Acropolis Investment Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 11.8% during the first quarter, Holdings Channel reports. The institutional investor owned 15,668 shares of the biopharmaceutical company’s stock after buying an additional 1,650 shares during the period. Acropolis Investment Management LLC’s holdings in Pfizer were worth $397,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter valued at about $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. Finally, UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.40 on Tuesday. The company has a market cap of $138.71 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50 day simple moving average of $23.11 and a 200 day simple moving average of $24.93. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.82 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.05%. The ex-dividend date was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.